uMed's Cardiometabolic Study Achieves Fast Milestone

uMed Enrolls Over 2,000 Patients in Record Time

uMed has reached a significant milestone by enrolling more than 2,000 participants in their AccessCMD Cardiometabolic Cohort within just four months.

This rapid increase demonstrates the dedication of patients to participate in research and showcases the effectiveness of uMed's model in facilitating access to research opportunities.

What is AccessCMD?

AccessCMD is an innovative registry and integrated clinical research platform that uses a decentralized model. It is approved by ethics committees and operates under a master protocol framework.

The platform, powered by uMed's ACCESS Research Platform, collaborates with numerous healthcare institutions in the UK and US to identify patients through health record data and engage them through various communication methods, including SMS, email, letters, and phone calls.

How Participants Contribute

Once invited to join the cohort, patients consent to be contacted again for additional data collection or to participate in further research studies. Participants share data from their Electronic Medical Records (EMR), genetic tests, wearable devices, and patient-reported surveys.

This data provides researchers with unique opportunities to explore novel endpoints within cardiometabolic diseases.

Relevance of Cardiometabolic Research

With increasing global rates of obesity and related health issues, cardiometabolic research has become a focal point for developing new therapies and tools to address these challenges.

Researchers often struggle with access to large, representative datasets, which are essential for developing effective treatments and understanding complex disease mechanisms.

Benefits for Researchers

The AccessCMD platform offers a solution by enabling the rapid collection of custom datasets, without needing to start studies from scratch. Researchers can quickly re-contact pre-consented patients to gather additional data.

This capability bridges the gaps left by static databases and site-based studies, making cardiometabolic research more efficient and effective.

Future Expansion Plans

AccessCMD is currently recruiting patients across the UK, with plans to expand to the US by the end of 2024.

The ongoing growth of the cohort underlines its potential to provide critical data for researchers and improve access to research for patients.